论文部分内容阅读
纤溶酶原活化剂 (PlasminogenActivator,PA)分为尿激酶型 (Urokinase ,uPA)和组织型 (TissuePA ,tPA)两种 ,二者水解纤溶酶原转变为纤溶酶 (plasmin) ,纤溶酶使纤维蛋白 (原 )降解。许多实验证明恶性肿瘤细胞具有浸润或转移的特征 ,其纤溶酶及活化剂的表达都较高 ,通过抑制肿瘤细胞纤溶酶原激活系统 ,可以降低肿瘤细胞的转移特征 ,为恶性肿瘤治疗开辟了一条新途径。测定肿瘤患者血浆tPA、uPA的含量 ,对于判断肿瘤是否转移、临床分期和预后 ,可能有着重要价值。
Plasminogen activator (PA) is divided into two types: urokinase (UPA) and tissue type (TissuePA, tPA), which hydrolyze plasminogen to plasmin, fibrinolysis Enzymes degrade fibrin (original). Many experiments show that malignant cells have the characteristics of infiltration or metastasis, the expression of plasmin and activators are high, by inhibiting tumor cell plasminogen activator system, can reduce the metastatic characteristics of tumor cells for the treatment of malignant tumors opened up A new way. Determining the plasma levels of tPA and uPA in tumor patients may have important value in judging whether tumor metastasis, clinical stage and prognosis.